Plain-English translation of NCT07777861 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether G01 Eye Drops can help slow or prevent vision loss in people with open-angle glaucoma who have already experienced damage to their optic nerve. Half of the participants will receive the new medication, and half will receive a placebo (fake drops that look identical), to fairly compare how well the treatment works. Researchers will track changes in vision and the health of the optic nerve over nearly a year to see if this treatment helps protect eyesight.
Open-angle glaucoma damages the optic nerve and causes progressive vision loss, and current treatments do not always prevent this damage. This trial is testing whether this new medication could offer additional protection to the optic nerve and help slow vision loss in people whose condition is worsening.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic multiple times over about 11 months (roughly 24 weeks of treatment plus follow-up visits). At each visit, you'll apply the assigned eye drops (either the new medication or placebo) to one eye according to the study schedule, and the research team will run several tests to measure your vision and eye health—including vision field tests, imaging of your optic nerve, and eye pressure checks. Some blood tests may also be done to check how the drops are working in your body.
AI-generated summary from trial data · Aug 25, 2026 · Not medical advice
China